Combination Epigenetic and Immunotherapy Overcomes Resistance to Monoclonal Antibodies in Hematologic Malignancies- A New Therapeutic Approach.

We recently reported that addition of epigenetic agents could overcome resistance of leukemic cells to a monoclonal antibody mediated antitumor effects in T cell prolymphocytic leukemia (TLL). We also described that epigenetic agents could induce the expression of the CD30 gene, thus providing a therapeutic target for the antibody drug conjugate brentuximab vedotin. Here we discuss these findings and their generality to treatment of other hematologic and solid malignancies.